Aller au contenu principal
Accès ouvert déclaré 2013 article

NEURO/MEDICAL ONCOLOGY

8Citations signalées, ce qui n’est pas une note de qualité
21Institutions déclarées
3Pays d’affiliation déclarés

Rattachement africain : us, in, jp. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: The treatment of patients with primary CNS lymphomas (PCNSL) has dramatically changed since the 1970's when whole brain radiation generated median survivals of about 12 months, significant neurotoxcity, and few long term survivors.High dose methotrexate (HD-MTX) monotherapy without radiation provides excellent response rates and 30% long term survivors without neurotoxicity.In general, relapses occur in the first two to four years after diagnosis and reports of very late relapses are rare.METHODS: Charts of all patients treated with HD-MTX monotherapy for newly diagnosed PCNSL between 1995 and 2012 at The Johns Hopkins Hospital were reviewed retrospectively.Patients with less than 5 years of follow-up data were excluded.First relapses over 10 years from diagnosis were identified and reviewed.RESULTS: Long-term follow-up data was available for 37 patients treated with HD-MTX monotherapy during this period.Four of 37 (11%) survived disease free for .10 years from initial diagnosis and maintain their excellent clinical status.All received methotrexate (8 gm/ m 2 ) every two weeks until complete response and then monthly to complete one year of therapy.Two of these long survivors (50%) presented with new seizures 10.8 and 11.2 years after initial diagnosis.Imaging revealed recurrent intraparenchymal disease, re-biopsy confirmed PCNSL in one, and both responded very well to retreatment with high dose methotrexate and Rituximab.The other two patients remain relapse free 12 and 13.7 years after initial diagnosis.CONCLUSION: Very late relapses have occurred in 2 of 4 long term survivors.These observations suggest that PCNSL patients treated with HD-MTX who were considered "cured" may be at substantial risk for late recurrences.A concerted effort to follow patients with this rare disease is needed to determine the frequency of late recurrences.More information is needed to determine if the addition of rituximab or other therapies reduce late recurrence rates. NO-002.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
NEURO/MEDICAL ONCOLOGY
Date Crossref
01/11/2013
Éditeur
Oxford University Press (OUP)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Glioma Diagnosis and TreatmentNeuroblastoma Research and TreatmentsCancer Treatment and Pharmacology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.